News for Appili Therapeutics Inc. (APLI.TO)

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key pipeline programs, engaged regulatory authorities on

Received overwhelming shareholder support in favour of take-private transaction with Aditxt

ADTX stock plunges to 52-week low, touches $0.18

Aditxt, Inc. (NASDAQ: ADTX) (”œAditxt” or the ”œCompany”), a social innovation platform dedicated to accelerating promising health innovations, today ann

Overwhelming shareholder support in favour of take-private transaction with Aditxt

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to it…

Aditxt moves to acquire Appili Therapeutics

Aditx Therapeutics stock hits 52-week low at $1.58

MOUNTAIN VIEW, Calif. — Aditxt, Inc. (“Aditxt” or “the Company”) (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promisi…

Aditxt shareholders approve strategic proposals

According to the latest research report published by DataM Intelligence, the Global Infectious Disease Testing Products Market was valued at US$ 27.8...

Visiongain has published a new report entitled Biodefence Market 2023-2033. It includes profiles of Biodefence Market and Forecasts, Market Segment by Size...

In recent years, the biodefense market has experienced significant growth due to increased government funding for biodefense programs and growing public...

Visiongain has published a new report entitled Biodefence Market 2023-2033. It includes profiles of Biodefence Market and Forecasts, Market Segment by Size...